Xigduo XR

Regulated Product — Business License Required

B2B and export product information for licensed and authorized business customers. Contact our team regarding bulk supply, documentation, and applicable commercial, import, and export requirements. This page is not a storefront and no purchasing, checkout, or pricing is offered here.

Product photography not yet supplied — this space will show official packaging imagery once provided by the business.

Product Overview

Xigduo XR combines dapagliflozin, an SGLT2 inhibitor, with extended-release metformin, a biguanide. It is prescribed for type 2 diabetes mellitus to manage high blood glucose — partly by removing excess glucose through the urine — and is described as helping to reduce the risk of diabetes-related complications.

Active ingredients
Dapagliflozin + Metformin hydrochloride (extended-release)
Dosage form
Extended-release oral tablet
Therapeutic class
SGLT2 inhibitor + biguanide
Regulatory status
Prescription / regulated — confirmed per enquiry and destination market
Availability
Confirmed per enquiry

Product Information

The following description reflects information associated with dapagliflozin and metformin and this product’s labelling. It has not been independently clinically verified by SDO Pharma and is provided for business and product-identification purposes only. It is not medical advice and does not replace the manufacturer’s official prescribing information.

Described Uses

  • Control of high blood glucose in type 2 diabetes mellitus, alongside diet and exercise
  • Described as helping the body remove excess glucose through the urine
  • Described as helping to reduce the risk of complications such as kidney damage, eye damage, and nerve issues
Note: SDO Pharma has not independently verified the manufacturer’s efficacy claims for this product and makes no additional medical or clinical claims beyond what is described here. We do not claim FDA, UAE, EU, or other specific regulatory approval for this product unless independently verified. This is a prescription / regulated-status product; patient dispensing is the responsibility of the licensed business customer, not SDO Pharma.

Described Dosage & Administration

  • Swallowed whole with food; not to be chewed, broken, or crushed
  • Taken at the same time each day, at the dose and duration prescribed
  • The full medication course should be completed to avoid serious effects

Described Side Effects

Commonly described side effects include:

  • Nausea, vomiting, and diarrhoea
  • Skin rash and taste change
  • Difficulty in urination
  • Low blood glucose (hypoglycaemia); tremor; dizziness; back pain

Any severe, persistent, or unexpected reaction requires prompt medical attention.

Precautions

  • Kidney or liver problems should be disclosed to the prescriber
  • Any use of “water pills” (diuretics) should be reported, given the risk of dehydration
  • Pregnancy or breastfeeding should be discussed with the prescriber
  • Excessive alcohol should be avoided, given the risk of lactic acidosis with metformin

This summary is provided for informational purposes only and does not replace the manufacturer’s official product labelling or professional medical advice.

B2B, Import & Export

B2B, Import & Export Enquiries

SDO Pharma supports business enquiries for pharmaceutical products, including bulk and export supply, subject to applicable licensing, regulatory, import, and export requirements. Requirements vary according to the destination market and the nature of the transaction.

We do not claim that this product is available for import into every country, and we do not claim FDA, UAE, EU, or other specific regulatory approval unless independently verified. Applicable documentation — including a valid Drug License, tax registration, and Importer Exporter Code (IEC) where relevant — is discussed directly with our team as part of the enquiry process. This is a regulated / prescription-status product supplied only to licensed and authorized business customers; SDO Pharma does not sell it directly to individual patients or consumers. See our Regulated Products Policy.

Product Enquiry

Request Product Information

Interested in this product for your business? Submit your enquiry and our team will contact you regarding bulk supply, documentation, and applicable requirements.

Frequently Asked Questions

Per its labelling, it combines dapagliflozin and extended-release metformin to control blood glucose in type 2 diabetes mellitus. SDO Pharma has not independently verified these claims.

Swallowed whole with food at the same time each day, without crushing or chewing, at the dose set by the prescriber.

Licensed and authorized business customers can submit the product enquiry form above or contact our team directly. Product availability, documentation, and supply arrangements are confirmed per enquiry.

Availability depends on the destination market’s regulatory requirements and cannot be confirmed without a direct enquiry. See our B2B, Import & Export Enquiries section above.

Explore More

Related Product Categories

SDO Pharma works across several pharmaceutical and healthcare product categories for business customers.

View Products & Services